

### 2022 ANNUAL MEETING SCHEDULE OF EVENTS

Thursday, June 16					
Start Time	End Time	Function	Location		
4:00 PM	6:00 PM	Registration	East CC Lobby		
6:00 PM	7:30 PM	Welcome Reception	Lakeview Terrace		

Friday, June 17				
Start Time	End Time	Function	Location	
6:30 AM	8:00 AM	Breakfast	Bay 1-2	
6:45 AM	8:00 AM	Executive Board Meeting	Boardroom 6	
7:00 AM	8:00 AM	Professional Photographer Headshots (complimentary)	Bay 1-2	
		Welcome & Opening Remarks		
8:00 AM	8:10 AM	Dr. Kathleen N. Moore, Dr. Andrew Li		
		General Session 1		
8:10 AM	9:13 AM	Moderators: Dr. Robert Giuntoli, Dr. Jayanthi Lea	Bay 3-4	
		Sentinel lymph node mapping for endometrial cancer in patients with morbid obesity		
8:10 AM	8:25 AM	Presenting Author: Nicole J. Fennimore, MD		
		Racial Differences in the Mutational Landscape of Serous Endometrial Cancer		
8:26 AM	8:41 AM	Presenting Author: Ruchi Garg, MD		
			d 10 and design where have all the action (	
0.42.414	0.57.414	Hysterectomies for endometrial hyperplasia decreased during the first year of the Covid-19 pandemic: where have all the patients gone?		
8:42 AM	8:57 AM	Presenting Author: Katherine Coakley, MD		
		MLH1 promoter hypermethylation among mismatch repair deficient, high-intermediate	risk, endometrial cancer patients is associated with	
		differences in prognostic factors		
8:58 AM	9:13 AM	Presenting Author: Marianne S. Hom-Tedla, MD		
9:15 AM	9:30 AM	Break	Bay 1-2	
		General Session 2		
9:30 AM	10:49 AM	Moderators: Dr. Edwin Alvarez, Dr. Jayanthi Lea	Bay 3-4	
	Pharmacologic inhibition of Discoidin Domain Receptor 2 (DDR2) sensitizes homologous recombination proficient ovarian ca		us recombination proficient ovarian cancer models to	
		treatment with olaparib.		
9:30 AM 9:45 AM Presenting Author: Elizabeth Stock, MD				
		Caged Rucaparib: Cancer Directed Delivery of PARPi		
9:46 AM	10:01 AM	Presenting Author: Nicole Marjon, MD, PhD		
		Targeting NF1/RAS pathway mutations in high-grade serous ovarian carcinoma (HGSOC) with a novel dual-mechanism ERK 1/2 inhibitor to		
		Targeting with the battway indiations in high-grade scrous ovarian caremonia (noso)		
		improve chemotherapy sensitivity		
10:02 AM	10 <sup>.</sup> 17 AM	improve chemotherapy sensitivity Presenting Author: Nicole Bubin, MD		
10:02 AM	10:17 AM	Presenting Author: Nicole Rubin, MD	· · ·	
		Presenting Author: Nicole Rubin, MD The PARP-1-DDX21-ribosome biogenesis axis is an alternative pathway targeted by PAR	· · ·	
10:02 AM	10:17 AM 10:33 AM	Presenting Author: Nicole Rubin, MD The PARP-1-DDX21-ribosome biogenesis axis is an alternative pathway targeted by PAR Presenting Author: Kevin M. Kremer, MD	P inhibitors in ovarian cancer	
10:18 AM	10:33 AM	Presenting Author: Nicole Rubin, MD The PARP-1-DDX21-ribosome biogenesis axis is an alternative pathway targeted by PAR Presenting Author: Kevin M. Kremer, MD Entinostat restores responsiveness to Olaparib in ID8 TP53 null and ID8 TP53 null/BR0	P inhibitors in ovarian cancer	
		Presenting Author: Nicole Rubin, MD The PARP-1-DDX21-ribosome biogenesis axis is an alternative pathway targeted by PAR Presenting Author: Kevin M. Kremer, MD Entinostat restores responsiveness to Olaparib in ID8 TP53 null and ID8 TP53 null/BRO Presenting Author: Tyler J. Woodard, MD	P inhibitors in ovarian cancer	
10:18 AM 10:34 AM	10:33 AM 10:49 AM	Presenting Author: Nicole Rubin, MD The PARP-1-DDX21-ribosome biogenesis axis is an alternative pathway targeted by PAR Presenting Author: Kevin M. Kremer, MD Entinostat restores responsiveness to Olaparib in ID8 TP53 null and ID8 TP53 null/BRO Presenting Author: Tyler J. Woodard, MD Tumor Board	AP inhibitors in ovarian cancer CA2 null mouse ovarian cancer cell lines	
10:18 AM 10:34 AM 10:50 AM	10:33 AM 10:49 AM 11:50 PM	Presenting Author: Nicole Rubin, MD The PARP-1-DDX21-ribosome biogenesis axis is an alternative pathway targeted by PAR Presenting Author: Kevin M. Kremer, MD Entinostat restores responsiveness to Olaparib in ID8 TP53 null and ID8 TP53 null/BR0 Presenting Author: Tyler J. Woodard, MD Tumor Board Moderators: Dr. Robert Giuntoli, Dr. Mae Zakhour	RP inhibitors in ovarian cancer CA2 null mouse ovarian cancer cell lines Bay 3-4	
10:18 AM 10:34 AM 10:50 AM 11:50 AM	10:33 AM 10:49 AM 11:50 PM 1:00 PM	Presenting Author: Nicole Rubin, MD The PARP-1-DDX21-ribosome biogenesis axis is an alternative pathway targeted by PAR Presenting Author: Kevin M. Kremer, MD Entinostat restores responsiveness to Olaparib in ID8 TP53 null and ID8 TP53 null/BR0 Presenting Author: Tyler J. Woodard, MD Tumor Board Moderators: Dr. Robert Giuntoli, Dr. Mae Zakhour Professional Photographer Headshots (complimentary)	RP inhibitors in ovarian cancer CA2 null mouse ovarian cancer cell lines Bay 3-4 Bay 1-2	
10:18 AM 10:34 AM 10:50 AM	10:33 AM 10:49 AM 11:50 PM	Presenting Author: Nicole Rubin, MD The PARP-1-DDX21-ribosome biogenesis axis is an alternative pathway targeted by PAR Presenting Author: Kevin M. Kremer, MD Entinostat restores responsiveness to Olaparib in ID8 TP53 null and ID8 TP53 null/BR0 Presenting Author: Tyler J. Woodard, MD Tumor Board Moderators: Dr. Robert Giuntoli, Dr. Mae Zakhour	RP inhibitors in ovarian cancer CA2 null mouse ovarian cancer cell lines Bay 3-4	



### 2022 ANNUAL MEETING SCHEDULE OF EVENTS

Saturday, June 1	18				
Start Time	End Time	Function	Location		
6:30 AM	8:00 AM	Breakfast	Bay 1-2		
		Trainee session: Jobs: Finding Your Happy			
7:00 AM	8:15 AM	Moderators: Dr. Kenneth Kim, Dr. Bobbie Rimel	The Shore Room		
7:15 AM	8:15 AM	WAGO Business Meeting	Bay 3-4		
		General Session 3			
8:30 AM	9:49 AM	Moderators: Dr. Amanika Kumar and Dr. Mae Zakhour	Bay 3-4		
		Increasing patient understanding of the relationship between Human Papillomavirus and cervical dysplasia through standardi			
		video education in an underserved patient population			
8:30 AM	8:45 AM	Presenting Author: Sydney P. Oesch, MD			
		Variation in VTE prophylaxis among gynecologic oncologists			
8:46 AM	9:01 AM	Presenting Author: Kyleigh M. Strickland, MD			
		Pre-operative Patient Characteristics Predict Outpatient Opioid Use			
9:02 AM	9:17 AM	Presenting Author: Alexandra Spirtos, MD			
		Four different postoperative analgesic approaches in patients converted from laparoscopic to open gynecologic tumor			
		surgery—trends and progress			
9:18 AM	9:33 AM	Presenting Author: Hyundeok Joo, MD			
2.207.00	5.007.00				
		Identifying the unmet social needs of gynecologic oncology patients in the safety net: comparing a self-administered screening tool to a cancer care navigation social work evaluation			
9:34 AM	9:49 AM	Presenting Author: Katherine Cotangco, MD			
9:50 AM	10:05 AM	Break	Bay 1-2		
5.50 AM	10.05 AM	General Session 4			
10:05 AM	11:08 AM	Moderators: Dr. Marla Scott, Dr. Christine Walsh	Bay 3-4		
		· ·			
		Characterization of the mutational landscape of high-grade serous ovarian cance	er pre- and post- neoadjuvant chemotherapy.		
10:05 AM	10:20 AM	M Presenting Author: Mark C. Valentine, MD, PhD			
		Clinical outcomes of patients with ovarian seromucinous tumors: A case series of 63 patients			
		Presenting Author: Dandi Huang, MD			
		In vitro transformation of ovarian surface epithelium links a mutation in SWI/SN	E Related Matrix Associated Actin Dependent		
		Regulator Of Chromatin, Subfamily A, Member 4 to familial small carcinoma of the ovary hypercalcemic type			
10:37 AM	10:52 AM	Presenting Author: Adam Krieg, PhD			
		Trends and Factors Associated with Cost of Hospitalization in Ovarian Cancer Cytoreductive Surgery: A National Perspective			
10:53 AM	11:08 AM	Presenting Author: Cortney M. Eakin, MD			
		Presidential Lecture: Financial Toxicity and Cancer in America			
11:10 AM	12:10 PM	Guest Speaker: Fumiko Chino, MD	Bay 3-4		
12:30 PM	2:00 PM	Industry Supported Symposium (The GOG Foundation, Inc. & Clovis Oncology)	Casco/Kidd/North Cape		
5:00 PM	6:00 PM	Professional Photographer Headshots (complimentary)	Bay 1-2		
		President's Reception			
		6:00pm Board boat cruise			
		6:30-7:00pm Cruise to event center			
		7:00-8:30pm President's Reception			
		8:30pm Board boat cruise			
		8:30-9:00pm Cruise back to resort			
6:00 PM	9:00 PM	Van shuttles will be available beginning at 7:30pm back to the resort	Hagadone Event Center		



### 2022 ANNUAL MEETING SCHEDULE OF EVENTS

Sunday, June 19	)			
Start Time	End Time	Function	Location	
6:00 AM	6:45 AM	Breakfast	Bay 1-2	
		Introduce WAGO 2023 Annual Meeting Location		
6:45 AM	7:00 AM	Dr. Andrew Li		
		ASCO Update		
7:00 AM	8:00 AM	Dr. Kathleen N. Moore	Bay 3-4	
		General Session 5		
8:00 AM	9:35 AM	Moderators: Dr. Robert Giuntoli, Dr. Renata Urban	Bay 3-4	
8:00 AM	8:15 AM	Hybrid Intracavitary and Interstitial Brachytherapy for Cervical Cancer in the Outpatient Setting Presenting Author: Gabriella L. Smith, MD		
8:16 AM	8:31 AM	Risks for complications and need for repeat excisional procedures of the uterine cervix Presenting Author: Katherine R. Robichaux		
8:32 AM	8:47 AM	The impact of the COVID pandemic on completion of radiation therapy for cervical cancer Presenting Author: Shelby Claire Liddell, MD		
8:48 AM	9:03 AM	Investigation of Adherence and Barriers for Posttreatment NCCN Surveillance Guidelines for Cervical Cancer Presenting Author: Christopher Mayer, MD, MS		
9:04 AM	9:19 AM	Opportunities Missed: Cervix Cancer Screening Failures in Women > 65 Presenting Author: Brandon I. Ing, MD, MHS		
0.20 444	0.05 444	Obesity as a post-operative risk factor for women undergoing open radical hysterectomy Presenting Author: Bethany Werner, MD		
9:20 AM 9:35 AM	9:35 AM			
9:35 AIVI	9:50 AM	Break	Bay 1-2	
9:50 AM	11:00 AM	General Session 6 & Closing Remarks	Day 2.4	
9:50 AIVI	11:00 Alvi	Moderators: Dr. Nolan Kinne, Dr. Christina Washington	Bay 3-4	
9:50 AM 10:05 A		Identifying HPV Vaccination Initiation Hot and Cold Spots and Associated Disparities in Texas Presenting Author: Lindsey K. Nguy, MD		
		Factors impacting genomic testing rates among epithelial ovarian cancer patients across a large community based healthcare system		
10:06 AM	10:21 AM	Presenting Author: Nicole M. Kretzer, MD PhD		
		Comparison of three testing strategies for germline genetic testing for homologous recombination deficiency mutations in women		
		with epithelial ovarian cancer		
10:22 AM	10:37 AM	Presenting Author: Elise M. Wilson, MD		
		Percutaneous interstitial brachytherapy ablation for targeting oligometastatic gynecologic cancers		
10:38 AM	10:53 AM	Presenting Author: Alex A. Francoeur, MD		
10:54 AM	11:00 AM	Closing Remarks	Bay 3-4	



WAGO is grateful for our 2022 Annual Meeting Commercial Supporters

## **GOLD SPONSORS**



# SILVER SPONSORS



### **BRONZE SPONSORS**



